A genome scale RNAi screen identifies GLI1 as a novel gene regulating vorinostat sensitivity

Cell Death and Differentiation

Volumn 23, Issue 7, 2016, Pages 1209-1218

  Falkenberg, K J ^a,c   Newbold, A ^a   Gould, C M ^a,d   Luu, J ^a   Trapani, J A ^a,b   Matthews, G M ^a,b,e   Simpson, K J ^a,b   Johnstone, R W ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^d GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR GLI1; VORINOSTAT; ANTINEOPLASTIC AGENT; BCL2L1 PROTEIN, HUMAN; CASPASE 3; CASPASE 7; GANT 61; GLI1 PROTEIN, HUMAN; HISTONE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; PROTEIN BCL 2; PROTEIN BCL X; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

APOPTOSIS; ARTICLE; DRUG RESISTANCE; EPIGENETIC REPRESSION; FUNCTIONAL GENOMICS; GENE CONTROL; GENE SILENCING; GENETIC ANALYSIS; GENETIC RESISTANCE; GENOME-WIDE ASSOCIATION STUDY; HCT116 CELL LINE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; PHARMACOGENETICS; PRIORITY JOURNAL; RNA INTERFERENCE; TRANSCRIPTION REGULATION; TUMOR CELL; ACETYLATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG POTENTIATION; GENETICS; HCT 116 CELL LINE; HUMAN GENOME; METABOLISM; TUMOR CELL LINE; UPREGULATION;

ACETYLATION; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; CASPASE 3; CASPASE 7; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENOME, HUMAN; HCT116 CELLS; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDROXAMIC ACIDS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIDINES; PYRIMIDINES; RNA INTERFERENCE; UP-REGULATION; ZINC FINGER PROTEIN GLI1;

EID: 84957916835     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2015.175     Document Type: Article

References (62)

1. Fantin VR, Richon VM. Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications. Clin Cancer Res 2007; 13: 7237-7242.
2. Fantin VR, Loboda A, Paweletz CP, Hendrickson RC, Pierce JW, Roth JA et al. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res 2008; 68: 3785-3794.
3. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-784.
4. Lindemann RK, Newbold A, Whitecross KF, Cluse LA, Frew AJ, Ellis L et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci USA 2007; 104: 8071-8076.
5. Bolden JE, Shi W, Jankowski K, Kan CY, Cluse L, Martin BP et al. HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. Cell Death Dis 2013; 4: e519.
6. Peart MJ, Tainton KM, Ruefli AA, Dear AE, Sedelies KA, O'Reilly LA et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 2003; 63: 4460-4471.
7. Fotheringham S, Epping MT, Stimson L, Khan O, Wood V, Pezzella F et al. Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitorinduced apoptosis. Cancer Cell 2009; 15: 57-66.
8. Khan O, Fotheringham S, Wood V, Stimson L, Zhang C, Pezzella F et al. HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc Natl Acad Sci USA 2010; 107: 6532-6537.
9. New M, Olzscha H, Liu G, Khan O, Stimson L, McGouran J et al. A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors. Cell Death Differ 2013; 20: 1306-1316.
10. Nijwening JH, Beijersbergen RL. Using large-scale RNAi screens to identify novel drug targets for cancer. IDrugs 2010; 13: 772-777.
11. Berns K, Hijmans EM, Mullenders J, Brummelkamp TR, Velds A, Heimerikx M et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 2004; 428: 431-437.
12. Tandle AT, Kramp T, Kil WJ, Halthore A, Gehlhaus K, Shankavaram U et al. Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation. Eur J Cancer 2013; 49: 3020-3028.
13. Mullenders J, von der Saal W, van Dongen MM, Reiff U, van Willigen R, Beijersbergen RL et al. Candidate biomarkers of response to an experimental cancer drug identified through a large-scale RNA interference genetic screen. Clin Cancer Res 2009; 15: 5811-5819.
14. Petrocca F, Altschuler G, Tan SM, Mendillo ML, Yan H, Jerry DJ et al. A Genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells. Cancer Cell 2013; 24: 182-196.
15. Postel-Vinay S, Bajrami I, Friboulet L, Elliott R, Fontebasso Y, Dorvault N et al. A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer. Oncogene 2013; 32: 5377-5387.
16. Fredebohm J, Wolf J, Hoheisel JD, Boettcher M. Depletion of RAD17 sensitizes pancreatic cancer cells to gemcitabine. J Cell Sci 2013; 126: 3380-3389.
17. Zhang S, Liu X, Zhang Y, Cheng Y, Li Y. RNAi screening identifies KAT8 as a key molecule important for cancer cell survival. Int J Clin Exp Pathol 2013; 6: 870-877.
18. Singel SM, Cornelius C, Batten K, Fasciani G,Wright WE, Lum L et al. A targeted RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in triple-negative breast cancer. Clin Cancer Res 2013; 19: 2061-2070.
19. Xie L, Gazin C, Park SM, Zhu LJ, Debily MA, Kittler EL et al. A synthetic interaction screen identifies factors selectively required for proliferation and TERT transcription in p53-deficient human cancer cells. PLoS Genet 2012; 8: e1003151.
20. Tsui M, Xie T, Orth JD, Carpenter AE, Rudnicki S, Kim S et al. An intermittent live cell imaging screen for siRNA enhancers and suppressors of a kinesin-5 inhibitor. PLoS One 2009; 4: e7339.
21. MacKeigan JP, Murphy LO, Blenis J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol 2005; 7: 591-600.
22. Falkenberg KJ, Gould CM, Johnstone RW, Simpson KJ. Genome-wide functional genomic and transcriptomic analyses for genes regulating sensitivity to vorinostat. Scientific Data 2014; 1: 140017.
23. Frankland-Searby S, Bhaumik SR. The 26 S proteasome complex: an attractive target for cancer therapy. Biochim Biophys Acta 2012; 1825: 64-76.
24. Fleischer TC, Yun UJ, Ayer DE. Identification and characterization of three new components of the mSin3A corepressor complex. Mol Cell Biol 2003; 23: 3456-3467.
25. Carpenter RL, Lo HW. Hedgehog pathway and GLI1 isoforms in human cancer. Discov Med 2012; 13: 105-113.
26. Lauth M, Bergstrom A, Shimokawa T, Toftgard R. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci USA 2007; 104: 8455-8460.
27. Fu J, Rodova M, Roy SK, Sharma J, Singh KP, Srivastava RK et al. GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft. Cancer Lett 2013; 330: 22-32.
28. Tomlins SA, Rubin MA, Chinnaiyan AM. Integrative biology of prostate cancer progression. Annu Rev Pathol 2006; 1: 243-271.
29. ClinicalTrials.gov: a service of the US National Institutes of Health (cited 29 August 2013); available at: clinicaltrials.gov; last accessed on 17 January 2016.
30. Fendrich V, Wiese D, Waldmann J, Lauth M, Heverhagen AE, Rehm J et al. Hedgehog inhibition with the orally bioavailable Smo antagonist LDE225 represses tumor growth and prolongs survival in a transgenic mouse model of islet cell neoplasms. Ann Surg 2011; 254: 818-823; discussion 823.
31. Ma H, Li HQ, Zhang X. Cyclopamine, a naturally occurring alkaloid, and its analogues may find wide applications in cancer therapy. Curr Top Med Chem 2013; 13: 2208-2215.
32. Matthews GM, Newbold A, Johnstone RW. Intrinsic and extrinsic apoptotic pathway signaling as determinants of histone deacetylase inhibitor antitumor activity. Adv Cancer Res 2012; 116: 165-197.
33. Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 2014; 13: 673-691.
34. Dhanyamraju PK, Holz PS, Finkernagel F, Fendrich V, Lauth M. Histone deacetylase 6 represents a novel drug target in the oncogenic Hedgehog signaling pathway. Mol Cancer Ther 2015; 14: 727-739.
35. Shevde LA, Samant RS. Nonclassical hedgehog-GLI signaling and its clinical implications. Int J Cancer 2014; 135: 1-6.
36. Wickstrom M, Dyberg C, Shimokawa T, Milosevic J, Baryawno N, Fuskevag OM et al. Targeting the hedgehog signal transduction pathway at the level of GLI inhibits neuroblastoma cell growth in vitro and in vivo. Int J Cancer 2013; 132: 1516-1524.
37. Gulino A, Di Marcotullio L, Canettieri G, De Smaele E, Screpanti I. Hedgehog/Gli control by ubiquitination/acetylation interplay. Vitam Horm 2012; 88: 211-227.
38. Huntzicker EG, Estay IS, Zhen H, Lokteva LA, Jackson PK, Oro AE. Dual degradation signals control Gli protein stability and tumor formation. Genes Dev 2006; 20: 276-281.
39. Di Marcotullio L, Ferretti E, Greco A, De Smaele E, Po A, Sico MA et al. Numb is a suppressor of Hedgehog signalling and targets Gli1 for Itch-dependent ubiquitination. Nat Cell Biol 2006; 8: 1415-1423.
40. Canettieri G, Di Marcotullio L, Greco A, Coni S, Antonucci L, Infante P et al. Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation. Nat Cell Biol 2010; 12: 132-142.
41. De Smaele E, Di Marcotullio L, Moretti M, Pelloni M, Occhione MA, Infante P et al. Identification and characterization of KCASH2 and KCASH3, 2 novel Cullin3 adaptors suppressing histone deacetylase and Hedgehog activity in medulloblastoma. Neoplasia 2011; 13: 374-385.
42. Gurung B, Feng Z, Hua X. Menin directly represses Gli1 expression independent of canonical Hedgehog signaling. Mol Cancer Res 2013; 11: 1215-1222.
43. Villegas VE, Rahman MF, Fernandez-Barrena MG, Diao Y, Liapi E, Sonkoly E et al. Identification of novel non-coding RNA-based negative feedback regulating the expression of the oncogenic transcription factor GLI1. Mol Oncol 2014; 8: 912-926.
44. Zhu W, You Z, Li T, Yu C, Tao G, Hu M et al. Correlation of hedgehog signal activation with chemoradiotherapy sensitivity and survival in esophageal squamous cell carcinomas. Jpn J Clin Oncol 2011; 41: 386-393.
45. Steg AD, Katre AA, Bevis KS, Ziebarth A, Dobbin ZC, Shah MM et al. Smoothened antagonists reverse taxane resistance in ovarian cancer. Mol Cancer Ther 2012; 11: 1587-1597.
46. Ramaswamy B, Lu Y, Teng KY, Nuovo G, Li X, Shapiro CL et al. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway. Cancer Res 2012; 72: 5048-5059.
47. Chen YJ, Lin CP, Hsu ML, Shieh HR, Chao NK, Chao KS. Sonic hedgehog signaling protects human hepatocellular carcinoma cells against ionizing radiation in an autocrine manner. Int J Radiat Oncol Biol Phys 2011; 80: 851-859.
48. Mozzetti S, Martinelli E, Raspaglio G, Prislei S, De Donato M, Filippetti F et al. Gli family transcription factors are drivers of patupilone resistance in ovarian cancer. Biochem Pharmacol 2012; 84: 1409-1418.
49. Das S, Samant RS, Shevde LA. Nonclassical activation of Hedgehog signaling enhances multidrug resistance and makes cancer cells refractory to Smoothened-targeting Hedgehog inhibition. J Biol Chem 2013; 288: 11824-11833.
50. Singh RR, Kunkalla K, Qu C, Schlette E, Neelapu SS, Samaniego F et al. ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. Oncogene 2011; 30: 4874-4886.
51. Cui D, Xu Q, Wang K, Che X. Gli1 is a potential target for alleviating multidrug resistance of gliomas. J Neurol Sci 2010; 288: 156-166.
52. Zahreddine HA, Culjkovic-Kraljacic B, Assouline S, Gendron P, Romeo AA, Morris SJ et al. The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. Nature 2014; 511: 90-93.
53. Bigelow RL, Chari NS, Unden AB, Spurgers KB, Lee S, Roop DR et al. Transcriptional regulation of bcl-2 mediated by the sonic hedgehog signaling pathway through gli-1. J Biol Chem 2004; 279: 1197-1205.
54. Katoh Y, Katoh M. Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr Mol Med 2009; 9: 873-886.
55. Regl G, Kasper M, Schnidar H, Eichberger T, Neill GW, Philpott MP et al. Activation of the BCL2 promoter in response to Hedgehog/GLI signal transduction is predominantly mediated by GLI2. Cancer Res 2004; 64: 7724-7731.
56. Wiegmans AP, Alsop AE, Bots M, Cluse LA, Williams SP, Banks KM et al. Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737. Cancer Res 2011; 71: 3603-3615.
57. Lin TL, Matsui W. Hedgehog pathway as a drug target: smoothened inhibitors in development. OncoTargets Ther 2012; 5: 47-58.
58. Falkenberg K, Saunders D, Simpson K. A high-throughput, multiplex cell death assay using an RNAi screening approach. Cold Spring Harbour Protocols 2014; 6: 663-676.
59. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc 2012; 7: 562-578.
60. Anders S, Pyl P, Huber W. HTSeq-A Python framework to work with high-throughput sequencing data. Bioinformatics 2015; 31: 166-169.
61. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010; 26: 139-140.
62. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3: 1-25.